Compare
Biomerica Inc vs Insight Molecular Diagnostics Inc. vs Aspira Women's Health Inc. vs Volitionrx Ltd
| Latest fiscal year | Biomerica Inc BMRA | Insight Molecular Diagnostics Inc. IMDX | Aspira Women's Health Inc. AWHL | Volitionrx Ltd VNRX |
|---|---|---|---|---|
| Year ended | 2026-05-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.45M | $4.05M | $9.22M | $1.73M |
| Revenue growth (YoY) | -16.2% | +115.6% | +0.4% | +40.0% |
| Gross margin | 8.1% | 56.7% | 64.2% | n/a |
| Operating margin | -119.5% | n/m | -85.9% | n/m |
| Net margin | -84.8% | n/m | -138.7% | n/m |
| Net income | -$3.77M | -$50.22M | -$12.78M | -$23.36M |
| EPS (Diluted) | -$1.30 | -$1.65 | -$0.37 | n/a |
| Operating cash flow | -$3.42M | -$22.18M | -$7.03M | -$19.68M |
| Free cash flow | n/a | -$25.37M | -$7.04M | -$19.77M |
| Cash & equivalents | $1.31M | $11.58M | $1.75M | $1.12M |
| Total assets | $6.76M | $25.76M | $5.46M | $6.90M |
| Total liabilities | $4.13M | $57.22M | $12.39M | $42.49M |
| Shareholders' equity | $2.63M | -$31.46M | -$6.93M | -$34.25M |
| Return on year-end equity | -143.5% | n/a | n/a | n/a |
| Shares outstanding | 3.20M | 28.68M | 43.48M | 125.78M |
Revenue, most recent five fiscal years
| Fiscal year | Biomerica Inc | Insight Molecular Diagnostics Inc. | Aspira Women's Health Inc. | Volitionrx Ltd |
|---|---|---|---|---|
| Latest | $4.45M Ended 2026-05-31 | $4.05M Ended 2025-12-31 | $9.22M Ended 2025-12-31 | $1.73M Ended 2025-12-31 |
| 1 year earlier | $5.31M Ended 2025-05-31 | $1.88M Ended 2024-12-31 | $9.18M Ended 2024-12-31 | $1.23M Ended 2024-12-31 |
| 2 years earlier | $5.42M Ended 2024-05-31 | $1.50M Ended 2023-12-31 | $9.15M Ended 2023-12-31 | $775.3K Ended 2023-12-31 |
| 3 years earlier | $5.34M Ended 2023-05-31 | $958.0K Ended 2022-12-31 | n/a | $306.4K Ended 2022-12-31 |
| 4 years earlier | $18.87M Ended 2022-05-31 | $2.20M Ended 2021-12-31 | n/a | $90.0K Ended 2021-12-31 |